Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2016—Visiun showcased its predictive analytics and population health reporting, which was added to its flagship product, Performance Insight. The predictive analytics, added to the comprehensive test-use module, are designed to enable laboratories to identify high-risk patients with both elevated patient risk and care gaps.
October 2016—Sekisui Diagnostics and Qualigen announced a strategic partnership encompassing current business and future collaboration opportunities. Sekisui Diagnostics has assumed commercial activities and distribution management for the FastPack IP System and associated products in U.S. and international markets.
October 2016—Gold Standard Diagnostics announced a strategic alliance with R-Biopharm AG (Darmstadt, Germany) to collaborate on multiple technology and marketing initiatives that will leverage the companies’ respective strengths in expanding product offerings and geographic sales coverage.
October 2016—Thermo Fisher Scientific exhibited its expanded offering of new assays, instruments, and software designed specifically for customers working in research and clinical settings. The Thermo Scientific DRI Hydrocodone assay detects hydrocodone in specimen samples and is FDA 510(k) cleared.
October 2016—BrandTech Scientific featured its line of Brand liquid handling products, including the Transferpette S single and multichannel pipettes optimized for handling sensitive clinical samples. The pipettes are designed for ergonomic, one-handed volume adjustment, are completely user serviceable and fully autoclavable, and are CE-IVD compliant.
October 2016—LGC Maine Standards announced its Validate D-Dimer calibration verification/linearity test kit has received 510(k) clearance for use on Instrumentation Laboratory’s ACL Top hemostasis test systems.
October 2016—Siemens Healthineers unveiled the Atellica Solution, a flexible immunoassay and clinical chemistry solution featuring patented bi-directional magnetic sample-transport technology that is 10 times faster than conventional conveyors, according to the company.
October 2016—Boston-based Oncolab’s AMAS test detects circulating antibodies to a specific antigen (protein) produced by most types of cancer. The AMAS test can be used as a diagnostic aid in cancer occurrence and recurrence. More than 60,000 tests have been performed, and both its sensitivity and specificity are over 90 percent.
October 2016—Fio Corp. exhibited the Fionet platform, a cloud-based connectivity and reporting platform that enables real-time oversight, fragile network connectivity, and actionable insights for medical device manufacturers and health care providers.
October 2016—Binding Site’s Immunological Group announced the addition of two rubella antigens and a cytomegalovirus antigen along with the availability of special protein reagents to in vitro diagnostic manufacturers.
The rubella antigens are derived and sourced from infected cells, via culture, which are then treated by UV irradiation to inactivate the pathogenic components. The ultra-purified and ultra-sensitive variant is ideal for the detection of IgM antibodies. The antigens are designed to benefit the needs of biopharmaceutical, clinical, and life science researchers, as well as manufacturers of IVD test kits, and exhibit exceptional purity levels as a result of cross-flow, ultra-filtration and centrifugation techniques.
